Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
about
Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiersInhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluationThe biopharmaceutical classification system of excipients.Global marine pollutants inhibit P-glycoprotein: Environmental levels, inhibitory effects, and cocrystal structureMass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pumpCost, effectiveness and environmental relevance of multidrug transporters in sea urchin embryos.Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function.Drug transporters and renal drug disposition in the newborn.Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.P-glycoprotein and membrane roles in multidrug resistance.Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells.Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance.Do adsorbed drugs onto P-glycoprotein influence its efflux capability?Permeation Enhancers for Intratympanically-applied Drugs Studied Using Fluorescent Dexamethasone as a Marker.
P2860
Q28282826-E83535B9-CE4B-4097-B529-C14867EFC7E1Q33399904-6FF74444-7585-4237-A14A-A9988D1362F5Q33902253-6806FD97-507B-4FE3-B919-0B7631A47A09Q36119605-66670E4D-0F29-4394-B3AC-A1210E7AA9E0Q36250024-0924EFEE-F9E2-412C-9533-7A8027760102Q36839792-03E0F5A1-E469-46DD-8737-671AFB9AA056Q36932440-879D95AB-1934-4F44-A46A-9740A992D285Q37200589-A35452D7-7CD9-4DBC-BCF6-E739B3C13815Q37371578-457A41AE-7811-433E-B211-9A2DCD10A035Q37394989-ED927EBD-69DE-45FD-B40F-2329640C2337Q37612789-67084060-BD30-40F5-8E5E-06D9C7B38B25Q37635181-7CBD73DE-CDCE-4252-B559-496DE890FFA9Q37668774-70F975C1-5584-4243-9A90-F080882C7680Q38523606-F3FA8D07-EB60-4F19-A9C9-5D78FEC89453Q39493601-F28415C1-C4AC-4038-8151-CE1219871F67Q41472858-0D1D6B59-2F9F-441D-B9ED-DBE94430787FQ47707597-80FBED95-C6E0-4554-83F2-3713AE2853DEQ53595926-D3F1402E-E6D2-4060-B240-40912D1B5B26Q53693469-E18955A0-5D63-4D13-88F5-F53E453A0A04
P2860
Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Modulation of P-glycoprotein-m ...... on across the plasma membrane.
@en
Modulation of P-glycoprotein-m ...... on across the plasma membrane.
@nl
type
label
Modulation of P-glycoprotein-m ...... on across the plasma membrane.
@en
Modulation of P-glycoprotein-m ...... on across the plasma membrane.
@nl
prefLabel
Modulation of P-glycoprotein-m ...... on across the plasma membrane.
@en
Modulation of P-glycoprotein-m ...... on across the plasma membrane.
@nl
P2093
P2860
P1433
P1476
Modulation of P-glycoprotein-m ...... on across the plasma membrane.
@en
P2093
Daniella Yeheskely-Hayon
Gera D Eytan
Hagar Katzir
Ronit Regev
P2860
P304
P356
10.1111/J.1742-4658.2007.06140.X
P407
P577
2007-11-06T00:00:00Z